TARIS Biomedical® is a clinical stage specialty pharmaceutical company focused on developing a pipeline of innovative treatments for bladder diseases. Current therapies for these conditions are characterized by limited efficacy and/or systemic side effects. The TARIS Biomedical® delivery platform is designed to improve treatment by providing controlled, sustained delivery of drug directly to target tissues. TARIS® is currently pursuing opportunities in bladder cancer, overactive bladder and Interstitial cystitis. The most advanced TARIS® product candidate, LiRIS®, is currently in Phase 2 clinical development for the treatment of interstitial cystitis.
Ed Kania is on the Board of Directors.